and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings ...
The gene therapy, which will be marketed in the United States with the brand name KEBILIDI (eladocagene exuparvovec-tneq), is indicated for the treatment of children and adults with AADC deficiency, ...
Q3 2024 Results Conference Call November 7, 2024 10:00 AM ETCompany ParticipantsJosh Carroll - Alpha IR Group, ...
Correspondence to: Dr J R de Kruijk, Department of Neurology, University Hospital Maastricht, P Debeylaan 25, NL 6229 HX Maastricht, The Netherlands; jdk{at}sneu.azm.nl Background: Outcome after mild ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
10hon MSN
The National Hurricane Center is monitoring Potential Tropical Cyclone 19, which could impact Florida sometime next week | ...
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...
This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.
Developed by PTC Therapeutics, Kebilidi is an adeno-associated virus vector ... Eight patients met new gross motor milestones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback